EAST NORRITON, Pa., Feb. 7, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion, will present at the upcoming 13th Annual BIO CEO & Investor Conference on Monday, February 14, 2011, at 2:00 p.m. EST. Dr. Nichtberger will also participate in a panel discussion titled "IPO Window-Creaking Open or Wide Open?" the following day on Tuesday, February 15, 2011, at 1:30 p.m. EST.
- A live audio webcast of the Company's presentation can be accessed at http://www.veracast.com/webcasts/bio/ceoinvestor2011/83110392.cfm or under "Calendar of Events" in the Investors section of the Company's website at www.tengion.com.
Dr. Nichtberger will also be presenting at the upcoming Leerink Swann "Hot Topics in Therapeutics" Roundtable Conference on Wednesday, February 16, 2011, at 9:35 a.m. EST. Dr. Nichtberger will also participate in the Emerging Platforms panel discussion at 10:45 a.m. EST that same day.
- A live audio webcast of the Company's presentation can be accessed at http://www.wsw.com/webcast/leerink20/tngn/ or under "Calendar of Events" in the Investors section of the Company's website at www.tengion.com.
Replays of both webcasts will be available in the Investors section of the Company's at www.tengion.com. Investors interested in listening to any live webcast are advised to log on before the start time in order to download any required software.
Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical program is the Neo-Kidney Augment™, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure. Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder. Tengion has worldwide rights to its product candidates. For more information, please visit www.tengion.com.
SOURCE Tengion, Inc.